<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Two-stage susceptibility: (internal carcinogen dose) × (damage-handling capacity) determines who progresses - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-9</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-9</p>
                <p><strong>Name:</strong> Two-stage susceptibility: (internal carcinogen dose) × (damage-handling capacity) determines who progresses</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why only some cigarette smokers develop lung cancer while others do not, despite smoking being a strong risk factor, based on the following results.</p>
                <p><strong>Description:</strong> Only some smokers develop lung cancer because smoking (external dose) is transformed into a highly variable internal genotoxic dose (reactive metabolites, DNA adduct burden, and lung-region deposition), and then filtered by equally variable host damage-handling capacity (detoxification, DNA repair, tumor-suppressor surveillance, and inflammatory tissue context). Cancer emerges when cumulative (internal dose) × (failure to neutralize/repair/eliminate damaged clones) exceeds a threshold over time. This explains why pack-years alone is an imperfect predictor: (i) genetic variants can change smoking behavior (exposure), (ii) metabolic variants can change internal dose per cigarette (activation/detox), (iii) repair/surveillance/inflammation can change the probability that damage is fixed and expands into a malignant clone, and (iv) co-exposures (PM2.5, radon, asbestos, biomass smoke) shift internal dose at the same smoking history.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5.2-2025-12-11</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Multiplicative risk surface for smokers (internal dose × damage-handling deficit)</h3>
            <p><strong>Statement:</strong> Among adult cigarette smokers, lung-cancer incidence hazard rises approximately on a multiplicative surface of effective internal carcinogen dose and impaired damage-handling capacity. A useful approximation is: log(Hazard) ≈ a + b·log(InternalDose) + c·(DamageHandlingDeficit) + d·log(InternalDose)·(DamageHandlingDeficit), where InternalDose aggregates tobacco and non-tobacco inhaled carcinogen burden (including deposition/topography) and DamageHandlingDeficit aggregates reduced detoxification/repair/surveillance and pro-carcinogenic tissue context (e.g., chronic inflammation). The interaction term predicts that susceptibility differences are most visible at high internal dose (heavy exposure) and/or high deficit (poor handling).</p>
            <p><strong>Domain/Scope:</strong> Applies to adult current/former cigarette smokers in populations where inhaled combustion-related carcinogens are the dominant etiologic exposures and where incidence (not just prognosis) is the endpoint; intended to explain inter-individual variability among smokers even at similar self-reported pack-years. Does not require tumor tissue, but can be tested with prospective biomarkers (internal dose, repair phenotypes, inflammatory markers).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>At very low smoking exposure (near-never or very light smokers), non-tobacco pathways (e.g., EGFR/ALK-driven etiologies) may dominate; the tobacco-derived InternalDose component becomes less explanatory.</li>
                <li>If smoking exposure is measured with large error (self-report), apparent exposure-independent genetic effects can reflect residual confounding; biomarker-verified exposure is needed to separate mediation from independence.</li>
                <li>In settings with extreme co-exposures (e.g., heavy asbestos, high radon, high biomass smoke), InternalDose must explicitly include these exposures or the model will misattribute risk to tobacco-related terms.</li>
                <li>The model is about incidence/susceptibility; post-diagnosis progression/mortality may follow additional dynamics (treatment, stage, tumor genotype) and can show different covariate signs depending on modeling choices.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Smoking shows strong dose–response yet only a minority of smokers develop lung cancer: long-term smokers RR ~10–30× vs never-smokers; heavy smokers cumulative risk up to ~30%; review notes ~"one in 9 smokers" develop lung cancer, implying substantial heterogeneity beyond exposure alone. <a href="../results/extraction-result-116.html#e116.2" class="evidence-link">[e116.2]</a> <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-116.html#e116.8" class="evidence-link">[e116.8]</a> <a href="../results/extraction-result-85.html#e85.0" class="evidence-link">[e85.0]</a> <a href="../results/extraction-result-89.html#e89.0" class="evidence-link">[e89.0]</a> </li>
    <li>Exposure assessment heterogeneity and internal dose variation are highlighted: depth of inhalation/compensation (e.g., low-yield/filter designs) can alter deposition and adenocarcinoma distribution; internal-dose biomarkers (cotinine, urinary carcinogen metabolites, DNA adducts) are emphasized as capturing heterogeneity not explained by pack-years. <a href="../results/extraction-result-116.html#e116.2" class="evidence-link">[e116.2]</a> <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-89.html#e89.10" class="evidence-link">[e89.10]</a> <a href="../results/extraction-result-89.html#e89.0" class="evidence-link">[e89.0]</a> </li>
    <li>Metabolic detoxification variation modifies smoker risk: GSTM1 null increases lung cancer odds overall and is stronger in smokers than non-smokers (OR smokers 1.34 vs non-smokers 1.20); dual-null GSTM1/GSTT1 increases risk more than single nulls; gene–gene interaction with CYP1A1 increases OR for combined genotypes. <a href="../results/extraction-result-79.html#e79.0" class="evidence-link">[e79.0]</a> </li>
    <li>DNA repair capacity/mutagen sensitivity is proposed to increase risk and to combine with smoking to produce greater-than-single-factor risk; candidate DNA repair polymorphisms and phenotypic assays are highlighted as sources of susceptibility heterogeneity. <a href="../results/extraction-result-116.html#e116.3" class="evidence-link">[e116.3]</a> </li>
    <li>Explicit high-dose interaction example: NAT2 slow-acetylation + mEH high-activity genotype shows ~2× increased risk in very heavy smokers (120 pack-years) but decreased risk in nonsmokers, implying strong effect modification by internal dose. <a href="../results/extraction-result-116.html#e116.1" class="evidence-link">[e116.1]</a> </li>
    <li>Strong gene×smoking synergy: germline TP53 mutation carriers who smoke are reported >3× more likely to develop lung cancer than non-smoking carriers, consistent with impaired surveillance/repair amplifying exposure effects. <a href="../results/extraction-result-89.html#e89.2" class="evidence-link">[e89.2]</a> <a href="../results/extraction-result-88.html#e88.0" class="evidence-link">[e88.0]</a> </li>
    <li>Preexisting inflammatory/structural lung disease creates large additional risk beyond smoking: COPD in lung cancer patients is common and can be strongly associated independent of smoking history (example OR 11.6 vs matched smokers), and idiopathic pulmonary fibrosis shows OR ~8.25 adjusted for smoking; CRP elevation associates with increased likelihood of lung cancer. <a href="../results/extraction-result-116.html#e116.5" class="evidence-link">[e116.5]</a> </li>
    <li>Additional inhaled/external carcinogens add to effective internal dose: ambient PM2.5 (Group 1 carcinogen) associates with ~8–19% increased lung cancer mortality per 10 μg/m3; radon contributes substantially to lung cancer deaths; occupational carcinogens (asbestos, silica, diesel) raise risk and can compound tobacco effects. <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-85.html#e85.3" class="evidence-link">[e85.3]</a> <a href="../results/extraction-result-89.html#e89.5" class="evidence-link">[e89.5]</a> <a href="../results/extraction-result-88.html#e88.8" class="evidence-link">[e88.8]</a> <a href="../results/extraction-result-89.html#e89.4" class="evidence-link">[e89.4]</a> <a href="../results/extraction-result-89.html#e89.3" class="evidence-link">[e89.3]</a> <a href="../results/extraction-result-85.html#e85.6" class="evidence-link">[e85.6]</a> <a href="../results/extraction-result-76.html#e76.1" class="evidence-link">[e76.1]</a> </li>
    <li>Model-based evidence of unmeasured heterogeneity among lung cancer patients: BLCS semi-competing risk modeling estimates sizable frailty variance (θ≈2.09; Kendall’s τ≈0.511) and nonlinear age×sex×smoking interactions, consistent with latent susceptibility subgroups beyond measured pack-years. <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Components are known, but the explicit multiplicative surface/threshold framework is a synthesis that yields clear interaction predictions (e.g., COPD modifying biomarker→risk slopes; GSTM1 modifying adducts conditional on cotinine/NNAL).</p>            <p><strong>What Already Exists:</strong> Multifactorial explanations for lung cancer in smokers (dose, metabolism, DNA repair, inflammation, and gene–environment interaction) are established in epidemiology and molecular carcinogenesis.</p>            <p><strong>What is Novel:</strong> The explicit, testable ‘risk surface’ framing that separates (internal dose) from (damage-handling deficit) and predicts strongest heterogeneity when both are high, while treating behavior-mediated exposure, detoxification genetics, repair phenotypes, and inflammatory lung disease as interacting axes rather than an additive checklist.</p>
        <p><strong>References:</strong> <ul>
    <li>Spitz et al. (2011) Lung cancer: epidemiology, etiology, and prevention [reviews dose, DNA repair/mutagen sensitivity, COPD, and gene–environment concepts]</li>
    <li>Hecht (2002) Tobacco carcinogens, their biomarkers and tobacco-induced cancer [internal dose and biomarker framework]</li>
    <li>Thorgeirsson et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease [behavior-mediated exposure genetics at 15q25]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Behavior-mediated exposure amplification (15q25 nicotinic receptor locus)</h3>
            <p><strong>Statement:</strong> In smokers, alleles at the 15q25 CHRNA5–CHRNA3–CHRNB4 locus increase lung cancer risk partly by increasing nicotine dependence, which increases effective cumulative exposure (internal dose) through higher intensity/duration and/or compensatory smoking patterns. This produces an allele-count dose–response on lung cancer risk that is expected to attenuate when true exposure is equalized or biomarker-verified.</p>
            <p><strong>Domain/Scope:</strong> Applies to adult populations where the 15q25 risk haplotypes are present and where smoking behavior is not externally constrained; most relevant among ever-smokers. Intended as a mediated pathway (gene → dependence/behavior → exposure) rather than a purely exposure-independent carcinogenic effect.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>If intensity/duration are constrained (e.g., enforced reduction, nicotine replacement eliminating inhaled carcinogens), the behavior-mediated component should diminish; any remaining association could reflect direct biological effects of nicotinic receptor signaling.</li>
                <li>Effect sizes may vary by ancestry, linkage disequilibrium structure, and how well smoking intensity/topography are measured.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Three independent genetic studies summarized in reviews report a marker at 15q25 with ~30% increased lung cancer risk for one copy and ~70–80% for two copies; region contains nicotinic receptor genes and is discussed as influencing nicotine dependence and thereby smoking exposure. <a href="../results/extraction-result-89.html#e89.1" class="evidence-link">[e89.1]</a> <a href="../results/extraction-result-88.html#e88.3" class="evidence-link">[e88.3]</a> </li>
    <li>Reviews explicitly frame the locus as potentially acting indirectly via addiction-driven higher exposure, and also note the alternative possibility of a direct biological susceptibility component. <a href="../results/extraction-result-88.html#e88.3" class="evidence-link">[e88.3]</a> <a href="../results/extraction-result-89.html#e89.1" class="evidence-link">[e89.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> The locus itself is established; the novelty is the theory-level role assignment and falsifiable mediation-vs-direct predictions within the unified model.</p>            <p><strong>What Already Exists:</strong> 15q25 is a well-replicated locus associated with nicotine dependence and lung cancer risk; mediation via smoking behavior is widely discussed.</p>            <p><strong>What is Novel:</strong> Positioning 15q25 as a prototype ‘behavioral exposure amplifier’ within a general internal-dose × damage-handling framework, with explicit prediction that biomarker-verified exposure equalization will attenuate the effect if mediation dominates.</p>
        <p><strong>References:</strong> <ul>
    <li>Thorgeirsson et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease [15q25 dependence + lung cancer association]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Exposure-independent conversion efficiency (5p15.33 TERT/CLPTM1L)</h3>
            <p><strong>Statement:</strong> Some germline loci increase lung cancer susceptibility largely independently of measured smoking dose by increasing ‘dose-to-cancer conversion efficiency’: for the same internal dose, carriers have a higher probability that damage persists and yields malignant clonal escape (e.g., via altered telomere maintenance or altered apoptosis under genotoxic stress).</p>
            <p><strong>Domain/Scope:</strong> Applies to common germline susceptibility loci with demonstrated smoking-adjusted associations and no association with cigarettes/day in controls; relevant to both smokers and never-smokers, and interpretable as primarily cell-intrinsic vulnerability rather than behavior-mediated exposure.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>If smoking dose is mismeasured (self-report), partial mediation could be missed; testing with internal-dose biomarkers could reveal some mediation even if cigarettes/day is null.</li>
                <li>Lead SNPs may tag causal variants; functional direction (TERT vs CLPTM1L) may differ by LD block and ancestry.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>GWAS identifies 5p15.33 (TERT/CLPTM1L) variants associated with lung cancer risk after adjustment for smoking exposure: rs402710 smoking-adjusted per-allele OR ≈1.19 (1.12–1.26); association seen in never-, ex-, and current smokers; rs402710 not associated with cigarettes/day among controls (p=0.74), arguing against behavior-mediated exposure effects in these data. <a href="../results/extraction-result-105.html#e105.0" class="evidence-link">[e105.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The association exists; the mechanistic class framing is a synthesis that yields new testable intermediate-phenotype predictions.</p>            <p><strong>What Already Exists:</strong> TERT/CLPTM1L is an established lung cancer susceptibility locus with effects persisting after smoking adjustment.</p>            <p><strong>What is Novel:</strong> Generalizing this into a mechanistic class—variants that alter per-unit-dose malignant escape probability (‘conversion efficiency’)—which suggests specific intermediate phenotypes (telomere length dynamics, apoptosis response) to measure prospectively in smokers.</p>
        <p><strong>References:</strong> <ul>
    <li>McKay et al. (2008) Lung cancer susceptibility locus at 5p15.33 [TERT/CLPTM1L smoking-adjusted association]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Inflammation/structural lung disease as a tissue-level gain factor</h3>
            <p><strong>Statement:</strong> In smokers, chronic inflammatory/structural lung disease (especially COPD/airflow obstruction and pulmonary fibrosis) amplifies carcinogenesis by increasing the probability that tobacco-induced mutations expand and progress (via repeated injury/repair, altered microenvironment, and possibly impaired clearance), producing large increases in lung cancer risk beyond smoking dose alone.</p>
            <p><strong>Domain/Scope:</strong> Applies to adult smokers with clinically or spirometrically defined COPD/airflow obstruction, emphysema, or fibrotic lung disease; pertains to lung cancer incidence/susceptibility (not only prognosis).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Reverse causation can inflate observed COPD associations if preclinical cancer impairs spirometry; prospective ascertainment reduces this risk.</li>
                <li>COPD can be both a mediator of smoking effects (on-pathway) and an effect modifier (changes slope of dose→risk); both roles can coexist.</li>
                <li>Different chronic lung diseases may amplify risk via distinct mechanisms (scarring/field effects in fibrosis/TB vs airway remodeling in COPD).</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Review evidence: COPD prevalent in 40–70% of lung cancer patients; one study reports 50% COPD prevalence in 602 lung cancer patients and OR 11.6 independent of age/gender/smoking history compared with matched smokers; idiopathic pulmonary fibrosis OR 8.25 after smoking adjustment; α1-antitrypsin carrier status ~2× risk after adjusting for smoking/COPD; CRP >3 mg/L associated with increased likelihood of lung cancer. <a href="../results/extraction-result-116.html#e116.5" class="evidence-link">[e116.5]</a> </li>
    <li>Another review notes ~5× lung cancer risk increase in smokers with COPD and increased risk associated with TB history (RR ~1.5 overall rising to ~2.0 after 20 years), consistent with chronic inflammation/scarring as risk amplifiers. <a href="../results/extraction-result-85.html#e85.2" class="evidence-link">[e85.2]</a> </li>
    <li>BLCS semi-competing risk modeling among NSCLC patients finds COPD associated with higher progression hazard (example HR≈1.39 under Xu method) and substantial latent heterogeneity, supporting the plausibility of strong tissue-context modifiers (though this is progression after diagnosis). <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> The associations are existing; the added value is the explicit interaction-centered formulation tied to biomarker slopes rather than only main effects.</p>            <p><strong>What Already Exists:</strong> COPD and pulmonary fibrosis are long-recognized correlates and potential risk factors for lung cancer; inflammation-driven carcinogenesis is a classic concept.</p>            <p><strong>What is Novel:</strong> Embedding COPD/fibrosis as an explicit ‘gain factor’ that modifies the internal-dose → cancer slope in a two-stage model, yielding direct interaction predictions with internal-dose biomarkers.</p>
        <p><strong>References:</strong> <ul>
    <li>Spitz et al. (2011) Lung cancer: epidemiology, etiology, and prevention [COPD/fibrosis and inflammation discussed as risk modifiers]</li>
    <li>Hubbard et al. (cited in reviews) Pulmonary fibrosis and lung cancer [fibrosis risk independent of smoking]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Among smokers matched on self-reported pack-years, those with higher internal-dose biomarkers (e.g., urinary tobacco carcinogen metabolites and/or airway DNA adduct burden) will have higher prospective lung cancer incidence; the association will strengthen when exposure is measured by biomarkers rather than pack-years.</li>
                <li>The predictive slope of internal-dose biomarkers for incident lung cancer will be steeper in smokers with COPD/airflow obstruction than in smokers without COPD (effect modification), even after adjusting for smoking history.</li>
                <li>In smokers, GSTM1-null individuals will show higher DNA adduct or oxidative DNA damage markers than GSTM1-present individuals at the same cotinine/NNAL level, consistent with reduced detoxification increasing internal effective genotoxicity.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A multiplicative composite index: (behavioral exposure amplifier score including 15q25) × (detox/repair deficit score including GSTM1 and DNA-repair phenotypes) × (inflammation score including CRP/COPD) will outperform additive models for absolute risk calibration and tail-risk stratification in heavy smokers; the magnitude of improvement (e.g., net reclassification) is uncertain.</li>
                <li>In a prospective cohort, 5p15.33 risk-allele carriers will display a measurable pre-cancer airway phenotype (e.g., altered telomere dynamics or reduced apoptosis after ex vivo genotoxic challenge) that mediates part of the genotype→incidence association and predicts risk beyond internal-dose biomarkers; effect size and feasibility are uncertain.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If, after rigorous biomarker verification of internal dose (cotinine/NNAL plus adducts), the GSTM1-null association with lung cancer incidence in smokers disappears entirely, it would challenge the claim that detoxification differences causally alter effective internal genotoxic dose (vs confounding).</li>
                <li>If prospective studies show COPD does not modify (interact with) internal-dose biomarkers in predicting incidence (i.e., identical biomarker→risk slopes in COPD and non-COPD smokers), it would weaken the ‘tissue-level gain factor’ statement (though COPD could still act as a mediator).</li>
                <li>In randomized smoking reduction/cessation interventions where biomarker-verified exposure is equalized across genotypes, if 15q25 genotype retains the same lung-cancer risk effect size, it would argue for a strong direct biological effect rather than primarily behavior-mediated exposure amplification.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Tumor-driver subtype enrichment in never/light smokers (EGFR, ALK) and fusion-driven etiologies indicates non-tobacco pathways that this smoker-focused internal-dose framework addresses only as special low-dose regimes rather than as primary drivers. <a href="../results/extraction-result-87.html#e87.1" class="evidence-link">[e87.1]</a> <a href="../results/extraction-result-89.html#e89.6" class="evidence-link">[e89.6]</a> <a href="../results/extraction-result-86.html#e86.1" class="evidence-link">[e86.1]</a> <a href="../results/extraction-result-87.html#e87.2" class="evidence-link">[e87.2]</a> <a href="../results/extraction-result-89.html#e89.8" class="evidence-link">[e89.8]</a> <a href="../results/extraction-result-88.html#e88.4" class="evidence-link">[e88.4]</a> <a href="../results/extraction-result-86.html#e86.0" class="evidence-link">[e86.0]</a> </li>
    <li>Assay/detection-platform variability (NGS vs FISH/direct sequencing; RNA availability for fusions) can distort observed molecular subtype frequencies and thus complicate mapping between exposure and ‘pathway’ categories. <a href="../results/extraction-result-86.html#e86.6" class="evidence-link">[e86.6]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>